Mistry Shailesh N, Shonberg Jeremy, Draper-Joyce Christopher J, Klein Herenbrink Carmen, Michino Mayako, Shi Lei, Christopoulos Arthur, Capuano Ben, Scammells Peter J, Lane J Robert
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville 3052, Victoria Australia.
Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University , 381 Royal Parade, Parkville 3052, Victoria Australia.
J Med Chem. 2015 Sep 10;58(17):6819-43. doi: 10.1021/acs.jmedchem.5b00585. Epub 2015 Aug 28.
Recently, we have demonstrated that N-((trans)-4-(2-(7-cyano-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)cyclohexyl)-1H-indole-2-carboxamide (SB269652) (1) adopts a bitopic pose at one protomer of a dopamine D2 receptor (D2R) dimer to negatively modulate the binding of dopamine at the other protomer. The 1H-indole-2-carboxamide moiety of 1 extends into a secondary pocket between the extracellular ends of TM2 and TM7 within the D2R protomer. To target this putative allosteric site, we generated and characterized fragments that include and extend from the 1H-indole-2-carboxamide moiety of 1. N-Isopropyl-1H-indole-2-carboxamide (3) displayed allosteric pharmacology and sensitivity to mutations of the same residues at the top of TM2 as was observed for 1. Using 3 as an "allosteric lead", we designed and synthesized an extensive fragment library to generate novel SAR and identify N-butyl-1H-indole-2-carboxamide (11d), which displayed both increased negative cooperativity and affinity for the D2R. These data illustrate that fragmentation of extended compounds can expose fragments with purely allosteric pharmacology.
最近,我们已经证明N-((反式)-4-(2-(7-氰基-3,4-二氢异喹啉-2(1H)-基)乙基)环己基)-1H-吲哚-2-甲酰胺(SB269652)(1)在多巴胺D2受体(D2R)二聚体的一个原体上采取双位点构象,以负向调节多巴胺在另一个原体上的结合。1的1H-吲哚-2-甲酰胺部分延伸到D2R原体中TM2和TM7细胞外末端之间的一个二级口袋中。为了靶向这个假定的变构位点,我们生成并表征了包括1的1H-吲哚-2-甲酰胺部分并从其延伸的片段。N-异丙基-1H-吲哚-2-甲酰胺(3)表现出变构药理学以及对TM2顶部相同残基突变的敏感性,这与1所观察到的情况相同。以3作为“变构先导物”,我们设计并合成了一个广泛的片段库,以产生新的构效关系并鉴定出N-丁基-1H-吲哚-2-甲酰胺(11d),其对D2R表现出增加的负协同性和亲和力。这些数据表明,扩展化合物的片段化可以暴露出具有纯变构药理学的片段。